Results 101 to 110 of about 14,464 (157)

Intravitreal Injection of Ziv-Aflibercept in Patient With Refractory Age-Related Macular Degeneration

, 2015
The results of a patient with exudative age-related macular degeneration who received an intravitreal injection of ziv-aflibercept (Zaltrap; Sanofi-Aventis, Paris, France) in the right eye are described.
Eduardo Büchele Rodrigues, Bueno de Moraes, Nilva Simeren [UNIFESP], Nilva Simeren Bueno de Moraes, Oliveira Dias, Joao Rafael de [UNIFESP], Farah, Michel Eid [UNIFESP], Rodrigues, Eduardo Buechele [UNIFESP], Camilla Oliveira Xavier, João Rafael de Oliveira Dias, Carsten Meyer, André Maia, Meyer, Carsten [UNIFESP], Michel Eid Farah, Xavier, Camilla Oliveira [UNIFESP], Maia, Andre [UNIFESP]   +13 more
core   +1 more source

Anti-tumor efficacy of anti-Dll4 (REGN1035) and anti-VEGF (ziv-aflibercept) in a sunitinib resistant RP-R-01 ccRCC patient-derived xenograft model.

, 2014
Mice with established subcutaneous tumors were treated with sunitinib for 4 weeks until tumor tissue was no longer responsive to treatment (tumor volume was ∼6 times that of pretreatment volume).
Mukund Seshadri (659823), Paula Sotomayor (186059), Alshad S. Lalani (659826), Li Shen (110858), Kiersten Marie Miles (659822), Dylan Conroy (659824), Frank Kuhnert (659825), Bryan Gillard (527902), Gavin Thurston (659827), Remi Adelaiye (197585), Roberto Pili (186063), Eric Ciamporcero (155252), Kristopher Attwood (318112)   +12 more
core   +1 more source

Intravitreal Ziv-Aflibercept versus Bevacizumab for Naïve Central Retinal Vein Occlusion with Macular Edema: An Interim Analysis of a Randomized Non-Inferiority Trial. [PDF]

Clin Ophthalmol, 2023
Sinawat S, Hemanak S, Chanthowong K, Sinawat S, Yospaiboon Y.   +4 more
europepmc   +1 more source

Intravitreal injections of ziv-aflibercept: in vitro and in vivo safety

, 2019
Objective: To access the cytotoxicity of two fusion proteins with vascular endothelial growth anti-factor action (ziv-aflibercept and aflibercept) on retinal pigment epithelium (RPE) cells and Muller-Glia cells in culture by assessing cell viability post
Andrade, Gabriel Costa De [UNIFESP]
core  

Effect of REGN1035 and/or anti-VEGF (sunitinib or ziv-aflibercept) treatment on tumor cell viability.

, 2014
Mice (8 mice/group) implanted with (A, B) RP-R-01 or (C) RP-R-02 tissues were treated with vehicle, sunitinib, or ziv-aflibercept and/or REGN1035. Tumors were harvested, processed, and tissue sections were stained for hematoxylin and eosin.
Mukund Seshadri (659823), Paula Sotomayor (186059), Alshad S. Lalani (659826), Li Shen (110858), Kiersten Marie Miles (659822), Dylan Conroy (659824), Frank Kuhnert (659825), Bryan Gillard (527902), Gavin Thurston (659827), Remi Adelaiye (197585), Roberto Pili (186063), Eric Ciamporcero (155252), Kristopher Attwood (318112)   +12 more
core   +1 more source

Anti-tumor efficacy of anti-Dll4 (REGN1035) and/or anti-VEGF (sunitinib or ziv-aflibercept) in RP-R-01 and RP-R-02 ccRCC patient derived xenografts.

, 2014
Mice (8 mice/group) were treated with vehicle, sunitinib, or ziv-aflibercept and/or REGN1035. Left panel: Tumor growth curves. (A) RP-R-01 REGN1035 and/or sunitinib treatment groups (B) RP-R-01 REGN1035 and/or ziv-aflibercept treatment groups (C) RP-R-02
Mukund Seshadri (659823), Paula Sotomayor (186059), Alshad S. Lalani (659826), Li Shen (110858), Kiersten Marie Miles (659822), Dylan Conroy (659824), Frank Kuhnert (659825), Bryan Gillard (527902), Gavin Thurston (659827), Remi Adelaiye (197585), Roberto Pili (186063), Eric Ciamporcero (155252), Kristopher Attwood (318112)   +12 more
core   +1 more source

Anti-VEGF agents in metastatic colorectal cancer (mCRC): are they all alike?

Cancer Management and Research, 2013
Muhammad Wasif Saif GI Oncology Program, Tufts University School of Medicine, Boston, MA, USA Abstract: Bevacizumab is a monoclonal antibody that binds and neutralizes vascular endothelial growth factor (VEGF)-A, a key player in the angiogenesis pathway.
Saif MW
doaj  

Effects of REGN1035 and/or ziv-aflibercept on tumor cell proliferation in RP-R-01 ccRCC xenograft.

, 2014
Mice were treated with vehicle, ziv-aflibercept and/or REGN1035. Tumors were harvested, processed, and tissue sections were stained for differential expression of Ki67. (A) Representative images.
Mukund Seshadri (659823), Paula Sotomayor (186059), Alshad S. Lalani (659826), Li Shen (110858), Kiersten Marie Miles (659822), Dylan Conroy (659824), Frank Kuhnert (659825), Bryan Gillard (527902), Gavin Thurston (659827), Remi Adelaiye (197585), Roberto Pili (186063), Eric Ciamporcero (155252), Kristopher Attwood (318112)   +12 more
core   +1 more source

Regression in polypoidal choroidal vasculopathy treated with ziv-aflibercept monotherapy - short term study. [PDF]

Saudi J Ophthalmol, 2021
Mishra SB, Singh SR, Goyal P, Chakurkar R, Govindhari V, Goud A, Chhablani J.   +6 more
europepmc   +1 more source

Aflibercept and Docetaxel Versus Docetaxel Alone After Platinum Failure in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer: A Randomized, Controlled Phase III Trial

, 2012
Purpose To compare the efficacy of aflibercept (ziv-aflibercept), a recombinant human fusion protein targeting the vascular endothelial growth factor (VEGF) pathway, with or without docetaxel in platinum-pretreated patients with advanced or metastatic ...
Ciuleanu, Tudor Eliade, Rey, Augustin, Ozguroglu, Mustafa, Goksel, Tuncay, Bennouna, Jaafar, Scagliotti, Giorgio, Shepherd, Frances A., Miller, Vincent, Thatcher, Nicholas, Novello, Silvia, Ramlau, Rodryg, Baldotto, Clarissa, Gorbunova, Vera, Le-Guennec, Solenn   +13 more
core   +1 more source